Chronic lymphocytic leukemia: disease biology

B cell receptor (BCR) signaling is crucial for normal B cell development and adaptive immunity. In chronic lymphocytic leukemia (CLL), the malignant B cells display many features of normal mature B lymphocytes, including the expression of functional B cell receptors (BCR). Cross talk between CLL cells and the microenvironment in secondary lymphatic organs results in BCR signaling and BCR-driven proliferation of the CLL cells. This critical pathomechanism can be targeted by blocking BCR-related kinases (BTK, PI3K, SYK) using small molecule inhibitors. Among these targets, Bruton tyrosine kinase (BTK) inhibitors have the highest therapeutic efficacy; they effectively block leukemia cell proliferation and generally induce durable remissions in CLL patients, even in patients with high-risk disease. By disrupting tissue homing receptor (i.e. chemokine receptor and adhesion molecule) signaling, these kinase inhibitors also mobilize CLL cells from the lymphatic tissues into the peripheral blood, causing a transient redistribution lymphocytosis, thereby depriving CLL cells from nurturing factors within the tissue niches. The clinical success of the BTK inhibitors in CLL underscore the central importance of the BCR in CLL pathogenesis. Here, we review CLL pathogenesis with a focus on the role of the BCR and other microenvironment cues.

Automated summary

B cell receptor signaling plays a crucial role in chronic lymphocytic leukemia (CLL). Targeting BCR-related kinases, such as Bruton tyrosine kinase (BTK), has shown high therapeutic efficacy by blocking CLL cell proliferation and inducing remissions. These kinase inhibitors also disrupt tissue homing receptor signaling, mobilizing CLL cells from lymphatic tissues into the peripheral blood.